nbamat Profile Banner
Nicolas A. Bamat, MD MSCE Profile
Nicolas A. Bamat, MD MSCE

@nbamat

Followers
3K
Following
6K
Statuses
4K

@ChildrensPhila @PennMedicine neonatologist & researcher; focus on Rx for neonatal lung disease. Ops lead @EBNEO. Assoc Ed @CochraneNeonate #NeoEBM 🇪🇨🇺🇸

Philadelphia, PA
Joined December 2012
Don't wanna be here? Send us removal request.
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
1 month
RT @DrAbdulRazak_MD: @EBNEO Let’s submit the votes for the most impactful publication! #neoEBM
0
2
0
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
1 month
RT @EBNEO: Select the finalists for the 2023 @EBNeo Impact Article of the Year! 👇 Which of these 8 great publica…
0
10
0
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
2 months
RT @EBNEO: Introducing the #EBNeoImpact23 nominees! This UCM vs DCC trial was published in Pediatrics - - and di…
0
2
0
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
2 months
RT @EBNEO: Introducing the #EBNeoImpact23 nominees! The IMPACT trial was published in Pediatrics - - & dissemina…
0
1
0
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
2 months
RT @Atul_Monash: Sharing our new paper led by @Dr_Rasheda with @BrianKingNeo @Dr_KSGautham & @souvik_neo (from workshop in #PAS2023) Navig…
0
9
0
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
2 months
@EBNEO @NEJM Looks like the CDC is recommending either Abrysvo or Beyfortus, but not both: We are certainly administering Beyfortus, but can't say we are routinely asking mothers if they received Abrysvo...
1
0
2
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
2 months
RT @EBNEO: Introducing the #EBNeoImpact23 nominees! The MATISSE trial was published in @NEJM - and disseminated v…
0
3
0
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
2 months
@BrianKingNeo @EBNEO @NEJM 👍👍 Particularly if they are costly and/or risk unnecessary treatment or intervention... Beware the cascade...
1
0
2
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
2 months
@EBNEO @NEJM We hadn't adopted cerebral NIRS prior to this trial. I am assuming some centers had? Would love to hear from providers in centers that were using it, and to know if this trial impacted their practice. Deimplementation can be even trickier than implementation!
0
0
1
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
2 months
RT @EBNEO: Introducing the #EBNeoImpact23 nominees! The SafeBoosC-III trial was published in @NEJM - - and dissemi…
0
2
0
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
2 months
RT @EBNEO: It's time for the 5th @EBNEO Impact Article of the Year campaign! We'll close 2024 by reviewing #neoebm highlights from 2023. A…
0
3
0
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
2 months
RT @EBNEO: ✅ Follow posts of their initial #ebneoalerts and #ebneoreviews in the coming days ✅ Vote for the 2 finalists & choose the most i…
0
4
0
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
2 months
RT @ambaln: #neotwitter What do you think are the major controversies in the field of bronchopulmonary dysplasia? If you've worked at multi…
0
4
0
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
2 months
@BrianKingNeo @drbretty @ambaln A couple of slides from my 2024 PAS presentation on this topic.
Tweet media one
Tweet media two
0
1
9
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
2 months
RT @nicupodcast: Our buddy @nbamat from @ebneo joins us to discuss polypharmacy and Furosemide use in the #nicu at @hottopicsneo! Keep an e…
0
1
0
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
6 months
@drbretty @MercyPerinatal @UniMelbMDHS @thewomens Congrats Brett!
1
0
1
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
8 months
@Olesya_oz Thank you!
0
0
1
@nbamat
Nicolas A. Bamat, MD MSCE
@nbamat
8 months
@dralexscrivens Hi Alex. They are, but usually through a paid subscription - I can access through EHR and/or uni library. Agree it would be interesting to see which drugs have discrepant dosing. Have recently become aware of wide discrepancies in IV --> enteral conversions for chlorothiazide
0
0
2